top of page
Insights for Life Sciences Talent Leaders
Strategic guidance on life sciences executive recruitment and human capital for search partners, biotech innovators, and scale-up HR leaders. I also share occasional personal reflections on the industry.


The True Cost of a Poor Senior Hire in Life Sciences
A poor senior hire in Life Sciences can cost far more than recruitment fees and replacement expenses. Delayed milestones, lost productivity, weakened trust, and reduced willingness to speak up can all affect organizational performance. This article explores the financial and cultural impact—and how to reduce the risk before making a pivotal appointment.
sharonshieldsconsu
6 days ago4 min read


Succession Planning in Life Sciences: Your Most Overlooked Risk Management Tool
Succession planning in the life sciences industry is not a “nice to have” HR process—it’s a core element of risk management and business continuity. Unplanned leadership gaps can delay clinical trials, regulatory submissions, manufacturing, and product launches, directly impacting patients and revenue. In this article, we explore when, why and how life sciences organisations should approach leadership succession, the mission‑critical roles to prioritise, and practical steps.
sharonshieldsconsu
Nov 73 min read


Remember, Remember the Fifth of November: Biotech’s Fireworks, Sparks and Slow Burns
Remember, remember the fifth of November—the night when bonfires burn, fireworks light the sky and everyone looks up to see what will explode next. Biotech has its own Fireworks Night. This year’s display featured headline-grabbing rockets: GLP‑1 deals, gene editing milestones, renewed enthusiasm for RNA and a more disciplined wave of AI‑in‑drug‑discovery stories. But, as every investor knows, not everything that launches reaches the same height.
For biotech insiders and inv
sharonshieldsconsu
Nov 53 min read


GLP-1s Beyond Obesity: What the Evidence Really Shows
GLP‑1 medicines have moved from metabolic workhorses to front-page news. Originally designed for diabetes, they now sit at the centre of conversations about obesity, cardiovascular risk – and increasingly, brain and cancer biology.
Beneath the headlines, two distinct questions are emerging for R&D and portfolio leaders:
In neurodegeneration, are GLP‑1s genuinely touching disease mechanisms in Alzheimer’s and Parkinson’s, or are they mainly cleaning up upstream metabolic and
sharonshieldsconsu
Sep 283 min read
bottom of page